IMCR
IMMUNOCORE HOLDINGS PLC-ADR
1 day chart
About IMCR
Immunocore Holdings plc is a commercial-stage biotechnology company. The Company is engaged in the development of a class of T cell receptor (TCR), bispecific immunotherapies called immune mobilizing monoclonal TCRs Against X disease (ImmTAX), which is designed to treat a range of diseases, including cancer, infectious and autoimmune. It is developing a pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia, and the United Kingdom. Its pipeline products include IMC-F106C, IMC-C103C, IMC-I109V, and IMC-M113V, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric, and others.
Buy US stocks in Australia starting with IMCR. Open an account and start investing today!
$2.50B
-
0.00%
243.74K
$52.36
$50.71
$51.41
$69.06
$43.00
IMCR FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in IMCR
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.